Knight Therapeutics Inc. (TSX:GUD)

Market Cap	805.07M +38.4%
Revenue (ttm)	510.45M +36.9%
Net Income	5.61M -49.3%
EPS	0.06 -43.4%
Shares Out	98.18M
PE Ratio	145.10
Forward PE	80.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,669
Open	8.23
Previous Close	8.24
Day's Range	8.12 - 8.27
52-Week Range	5.66 - 8.90
Beta	0.04
Analysts	Strong Buy
Price Target	9.83 (+19.88%)
Earnings Date	May 7, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 830
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD

Analyst Summary

According to 7 analysts, the average rating for GUD stock is "Strong Buy." The 12-month stock price target is $9.83, which is an increase of 19.88% from the latest price.

Price Target

$9.83

(19.88% upside)

Analyst Consensus: Strong Buy